切换至 "中华医学电子期刊资源库"
高级检索
中华妇幼临床医学杂志(电子版)

中华妇幼临床医学杂志(电子版) ›› 2024, Vol. 20 ›› Issue (02) : 157 -165. doi: 10.3877/cma.j.issn.1673-5250.2024.02.005

专题论坛

外阴白色病变病因研究及治疗现状
杨琳1, 尹如铁1,†()   
  1. 1. 四川大学华西第二医院妇产科、出生缺陷与相关妇儿疾病教育部重点实验室，成都　610041
  • 收稿日期:2023-10-30 修回日期:2024-03-12 出版日期:2024-04-01
  • 通信作者: 尹如铁

Current research status on etiology and treatment of patients with white lesions of vulva

Lin Yang1, Rutie Yin1,†()   

  1. 1. Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
  • Received:2023-10-30 Revised:2024-03-12 Published:2024-04-01
  • Corresponding author: Rutie Yin
  • Supported by:
    Key Research and Development Project of Department of Science and Technology of Sichuan Province(2019YFS0532); Key Research and Development Project of Chengdu(2021-YF05-01725-SN); " Two Cancers" Screening Appropriate Technology Base (Teacher Training) Project of Sichuan Health Commission(2022JDXM001)
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

杨琳, 尹如铁. 外阴白色病变病因研究及治疗现状[J]. 中华妇幼临床医学杂志(电子版), 2024, 20(02): 157-165.

Lin Yang, Rutie Yin. Current research status on etiology and treatment of patients with white lesions of vulva[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(02): 157-165.

外阴白色病变(WLV)是与遗传、免疫、炎症、代谢等多种因素相关所致的一组外阴局部皮肤病变，恶变率为(2～25)/104，目前国内外妇产科及皮肤科学术界对WLV的认识尚未统一，约10%无症状WLV患者可能被临床漏诊或误诊。目前临床对WLV患者的治疗方案，亦尚存在较大差异。笔者拟就本病病因及治疗最新研究现状进行阐述，旨在为WLV患者的临床诊断和治疗提供参考。

关键词: 外阴白色病变, 外阴硬化性苔藓, 瘙痒症，外阴, 免疫，黏膜, 胶原病, 炎症趋化因子类, 药物疗法, 物理治疗方法, 激光疗法, 女(雌)性

White lesion of vulva (WLV) is a group of local vulvar skin lesions associated with genetics, immunity, inflammation, metabolism and other factors. The malignant transformation rate of WLV is (2-25)/104. At present, the understanding of WLV in obstetrics, gynecology and dermatology academic circles at home and abroad has not yet been unified. Nearly 10% of asymptomatic WLV patients may be clinically missed or misdiagnosed. There are also great differences in treatment options. The authors will elaborate the research status of etiology and treatment of WLV, in order to provide reference for the clinical diagnosis and treatment of patients with WLV.

Key words: White lesion of vulva, Vulvar lichen sclerosus, Pruritus vulvae, Immunity, mucosal, Collagen diseases, Chemokines, Drug therapy, Physical therapy modalities, Laser therapy, Female
[1]
Preti M, Borella F, Ferretti S, et al. Genital and extragenital oncological risk in women with vulvar lichen sclerosus: a multi-center Italian study[J]. Maturitas, 2023, 175: 107767. DOI: 10.1016/j.maturitas.
[2]
Steinkasserer L, Hachenberg J, Hillemanns P, et al. Characterization of patients with vulvar lichen sclerosus and association to vulvar carcinoma: a retrospective single center analysis[J]. Arch Gynecol Obstet, 2023, 307(6): 1921-1928. DOI: 10.1007/s00404-022-06848-y.
[3]
Grassi S, Tadiotto Cicogna G, Magri F, et al. Frontal fibrosing alopecia and genital lichen sclerosus: Single-center experience[J]. J Cosmet Dermatol, 2021, 20(2): 615-620. DOI: 10.1111/jocd.13573.
[4]
Tran DA, Tan X, Macri CJ, et al. Lichen sclerosus: an autoimmunopathogenic and genomic enigma with emerging genetic and immune targets[J]. Int J Biol Sci, 2019, 15(7): 1429-1439. DOI: 10.7150/ijbs.34613.
[5]
Haefner HK, Welch KC, Rolston AM, et al. Genomic profiling of vulvar lichen sclerosus patients shows possible pathogenetic disease mechanisms[J]. J Low Genit Tract Dis, 2019, 23(3): 214-219. DOI: 10.1097/LGT.0000000000000482.
[6]
Bieber AK, Steuer AB, Melnick LE, et al. Autoimmune and dermatologic conditions associated with lichen sclerosus[J]. J Am Acad Dermatol, 2021, 85(1): 228-229. DOI: 10.1016/j.jaad.
[7]
Corazza M, Schettini N, Zedde P, et al. Vulvar lichen sclerosus from pathophysiology to therapeutic approaches: evidence and prospects[J]. Biomedicines, 2021, 9(8): 950. DOI: 10.3390/biomedicines9080950.
[8]
Yang K. Regulation of treg cell metabolism and function in non-lymphoid tissues[J]. Front Immunol. 2022, 13: 909705. DOI: 10.3389/fimmu.2022.909705.
[9]
Sawant DV, Yano H, Chikina M, et al. Adaptive plasticity of IL-10＋ and IL-35＋ Treg cells cooperatively promotes tumor T cell exhaustion[J]. Nat Immunol, 2019, 20(6): 724-735. DOI: 10.1038/s41590-019-0346-9.
[10]
Paulis G, Berardesca E. Lichen sclerosus: the role of oxidative stress in the pathogenesis of the disease and its possible transformation into carcinoma[J]. Res Rep Urol, 2019, 11: 223-232. DOI: 10.2147/RRU.S205184.
[11]
Fancher K, Gardner JM, Shalin SC. Elastophagocytosis and interstitial granulomatous infiltrate are more common in extragenital vs genital lichen sclerosus[J]. J Cutan Pathol, 2020, 47(10): 903-912. DOI: 10.1111/cup.13741.
[12]
Zhao Y, Zhao S, Li H, et al. Expression of galectin-7 in vulvar lichen sclerosus and its effect on dermal fibroblasts[J]. Oncol Lett, 2018, 16(2): 2559-2564. DOI: 10.3892/ol.2018.8897.
[13]
Shim TN, Harwood CA, Marsh SG，et al. Immunogenetics and human papillomavirus (HPV) in male genital lichen sclerosus (MGLSc) [J]. Int J STD AIDS, 2020, 31(14): 1334-1339. DOI: 10.1177/0956462420949395.
[14]
Salem I, Ramser A, Isham N, et al. The gut microbiome as a major regulator of the gut-skin axis[J]. Front Microbiol, 2018, 9: 1459. DOI: 10.3389/fmicb.2018.01459.
[15]
Chattopadhyay S, Arnold JD, Malayil L, et al. Potential role of the skin and gut microbiota in premenarchal vulvar lichen sclerosus: a pilot case-control study[J]. PLoS One, 2021, 16(1): e0245243. DOI: 10.1371/journal.pone.0245243.
[16]
De Giorgi V, Scarfì F, Silvestri F, et al. Genital piercing: a warning for the risk of vulvar lichen sclerosus[J]. Dermatol Ther, 2021, 34(1): e14703. DOI: 10.1111/dth.14703.
[17]
Carlson JA, Murphy M. Androgen receptors and lichen sclerosus[J]. J Am Acad Dermatol, 2000, 43(3): 559-560. DOI: 10.1067/mjd.2000.109276.
[18]
Borghi A, Corazza M. Novel therapeutic approaches and targets for treatment of vulvar lichen sclerosus[J]. Curr Pharm Biotechnol, 2021, 22(1): 99-114. DOI: 10.2174/1389201021666200516154310.
[19]
Kirtschig G, Becker K, Günthert A, et al. Evidence-based (S3) guideline on (anogenital) lichen sclerosus[J]. J Eur Acad Dermatol Venereol, 2015, 29(10): e1-43. DOI: 10.1111/jdv.13136.
[20]
Lewis FM, Tatnall FM, Velangi SS, et al. British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018[J]. Br J Dermatol, 2018, 178(4): 839-853. DOI: 10.1111/bjd.16241.
[21]
Lee A, Bradford J, Fischer G. Long-term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women[J]. JAMA Dermatol, 2015, 151(10): 1061-1067. DOI: 10.1001/jamadermatol.2015.0643.
[22]
Papini M, Russo A, Simonetti O, et al. Diagnosis and management of cutaneous and anogenital lichen sclerosus: recommendations from the Italian Society of Dermatology (SIDeMaST) [J]. Ital J Dermatol Venerol, 2021, 156(5): 519-533. DOI: 10.23736/S2784-8671.21.06764-X.
[23]
Mazzilli S, Diluvio L, Di Prete M, et al. Tacrolimus 0.03% ointment for treatment of paediatric lichen sclerosus: a case series and literature review[J]. J Int Med Res, 2018, 46(9): 3724-3728. DOI: 10.1177/0300060518778219.
[24]
Kim GW, Park HJ, Kim HS, et al. Topical tacrolimus ointment for the treatment of lichen sclerosus, comparing genital and extragenital involvement[J]. J Dermatol, 2012, 39(2): 145-150. DOI: 10.1111/j.1346-8138.2011.01384.x.
[25]
Funaro D, Lovett A, Leroux N，et al. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus[J]. J Am Acad Dermatol, 2014, 71(1): 84-91. DOI: 10.1016/j.jaad.2014.02.019.
[26]
Frieder J, Kivelevitch D, Menter A. Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature[J]. Ther Deliv, 2017, 8(9): 737-746. DOI: 10.4155/tde-2017-0058.
[27]
Gupta S, Saraswat A, Kumar B. Treatment of genital lichen sclerosus with topical calcipotriol[J]. Int J STD AIDS, 2005, 16(11): 772-774. DOI: 10.1258/095646205774763234.
[28]
Borghi A, Corazza M, Minghetti S, et al. Topical tretinoin in the treatment of vulvar lichen sclerosus: an advisable option? [J]. Eur J Dermatol, 2015, 25(5): 404-409. DOI: 10.1684/ejd.2015.2595.
[29]
Borghi A, Corazza M, Minghetti S, et al. Avocado and soybean extracts as active principles in the treatment of mild-to-moderate vulvar lichen sclerosus: results of efficacy and tolerability[J]. J Eur Acad Dermatol Venereol, 2015, 29(6): 1225-1230. DOI: 10.1111/jdv.12617.
[30]
Simental-Mendía M, Sánchez-García A, Acosta-Olivo CA, et al. Efficacy and safety of avocado-soybean unsaponifiables for the treatment of hip and knee osteoarthritis: a systematic review and Meta-analysis of randomized placebo-controlled trials[J]. Int J Rheum Dis, 2019, 22(9): 1607-1615. DOI: 10.1111/1756-185X.13658.
[31]
Gerkowicz A, Szczepanik-Kułak P, Krasowska D. Photodynamic therapy in the treatment of vulvar lichen sclerosus: a systematic review of the literature[J]. J Clin Med, 2021, 10(23): 5491. DOI: 10.3390/jcm10235491.
[32]
Gunaydin G, Gedik ME, Ayan S. Photodynamic therapy for the treatment and diagnosis of cancer-a review of the current clinical status[J]. Front Chem, 2021, 9: 686303. DOI: 10.3389/fchem.2021.686303.
[33]
Liu J, Hao J, Wang Y，et al. Clinical and dermoscopic assessment of vulvar lichen sclerosus after 5-aminolevulinic acid photodynamic therapy: a prospective study[J]. Photodiagnosis Photodyn Ther, 2021, 33: 102109. DOI: 10.1016/j.pdpdt.2020.102109.
[34]
Qing C, Mao X, Liu G, et al. The efficacy and safety of 5-aminolevulinic acid photodynamic therapy for lichen sclerosus: a Meta analysis[J]. Indian J Dermatol, 2023, 68(1): 1-7. DOI: 10.4103/ijd.ijd_925_21.
[35]
Filippini M, Sozzi J, Farinelli M, et al. Effects of fractional CO2 laser treatment on patients affected by vulvar lichen sclerosus: a prospective study[J]. Photobiomodul Photomed Laser Surg, 2021, 39(12): 782-788. DOI: 10.1089/photob.2021.0053.
[36]
Mitchell L, Goldstein AT, Heller D, et al. Fractionated carbon dioxide laser for the treatment of vulvar lichen sclerosus: a randomized controlled trial[J]. Obstet Gynecol, 2021, 137(6): 979-987. DOI: 10.1097/AOG.0000000000004409.
[37]
Burkett LS, Siddique M, Zeymo A, et al. Clobetasol compared with fractionated carbon dioxide laser for lichen sclerosus: a randomized controlled trial[J]. Obstet Gynecol, 2021, 137(6): 968-978. DOI: 10.1097/AOG.0000000000004332.
[38]
Zhong X, Zhang M, Tian Z, et al. The study of enhanced high-intensity focused ultrasound therapy by sonodynamic N2O microbubbles[J]. Nanoscale Res Lett, 2019, 14(1): 381. DOI: 10.1186/s11671-019-3219-0.
[39]
Ye M, Deng X, Mao S, et al. High intensity focused ultrasound treatment for non-neoplastic epithelial disorders of the vulva: factors affecting effectiveness and recurrence[J]. Int J Hyperthermia, 2015, 31(7): 771-776. DOI: 10.3109/02656736.2015.1053101.
[40]
Wu C, Zou M, Xiong Y, et al. Short- and long-term efficacy of focused ultrasound therapy for non-neoplastic epithelial disorders of the vulva[J]. BJOG, 2017, 124(Suppl 3): 87-92. DOI: 10.1111/1471-0528.14747.
[41]
Feng T, Wang L, Zhu D, et al. Factors influencing the clinical efficacy of high-intensity focused ultrasound in the treatment of non-neoplastic epithelial disorders of the vulva: a retrospective observational study[J]. Int J Hyperthermia, 2021, 38(1): 1457-1461. DOI: 10.1080/02656736.2021.1985628.
[42]
Zhou W, Zhu L, Zhou H, et al. The efficacy of high-intensity, focused ultrasound treatment for non-neoplastic epithelial disorders of the vulva[J]. Cell Mol Biol (Noisy-le-grand), 2016, 62(4): 111-115.
[43]
Chung ASJ, Suarez OA. Current treatment of lichen sclerosus and stricture[J]. World J Urol, 2020, 38(12): 3061-3067. DOI: 10.1007/s00345-019-03030-z.
[44]
Singh N, Mishra N, Ghatage P. Treatment options in vulvar lichen sclerosus: a scoping review[J]. Cureus, 2021, 13(2): e13527. DOI: 10.7759/cureus.13527.
[45]
Chmel R, Nováčková M, Fait T, et al. Clitoral phimosis: effects on female sexual function and surgical treatment outcomes[J]. J Sex Med, 2019, 16(2): 257-266. DOI: 10.1016/j.jsxm.2018.12.012.
[46]
Jiang W, Wang J, Lin J, et al. Adipose-derived stem cell-enriched lipotransfer reverses skin sclerosis by suppressing dermal inflammation[J]. Plast Reconstr Surg, 2022, 150(3): 578-587. DOI: 10.1097/PRS.0000000000009435.
[47]
Abu-Ghname A, Perdanasari AT, Reece EM. Principles and applications of fat grafting in plastic surgery[J]. Semin Plast Surg, 2019, 33(3): 147-154. DOI: 10.1055/s-0039-1693438.
[48]
Casabona F, Priano V, Vallerino V, et al. New surgical approach to lichen sclerosus of the vulva: the role of adipose-derived mesenchymal cells and platelet-rich plasma in tissue regeneration[J]. Plast Reconstr Surg, 2010, 126(4): 210e-211e. DOI: 10.1097/PRS.0b013e3181ea9386.
[49]
Almadori A, Hansen E, Boyle D, et al. Fat grafting improves fibrosis and scarring in vulvar lichen sclerosus: results from a prospective cohort study[J]. J Low Genit Tract Dis, 2020, 24(3): 305-310. DOI: 10.1097/LGT.0000000000000520.
[50]
Monreal J. Safety and efficacy of stromal vascular fraction enriched fat grafting therapy for vulvar lichen sclerosus[J]. Cureus, 2020, 12(2): e7096. DOI: 10.7759/cureus.7096.
[51]
Goldstein AT, Mitchell L, Govind V, et al. A randomized double-blind placebo-controlled trial of autologous platelet-rich plasma intradermal injections for the treatment of vulvar lichen sclerosus[J]. J Am Acad Dermatol, 2019, 80(6): 1788-1789. DOI: 10.1016/j.jaad.2018.12.060.
[52]
Tedesco M, Bellei B, Garelli V, et al. Adipose tissue stromal vascular fraction and adipose tissue stromal vascular fraction plus platelet-rich plasma grafting: new regenerative perspectives in genital lichen sclerosus[J]. Dermatol Ther, 2020, 33(6): e14277. DOI: 10.1111/dth.14277.
[53]
Tedesco M, Pranteda G, Chichierchia G, et al. The use of PRP (platelet-rich plasma) in patients affected by genital lichen sclerosus: clinical analysis and results[J]. J Eur Acad Dermatol Venereol, 2019, 33(2): e58-e59. DOI: 10.1111/jdv.15190.
[54]
Eshtiaghi P, Sadownik LA. Fact or fiction? Adipose-derived stem cells and platelet-rich plasma for the treatment of vulvar lichen sclerosus[J]. J Low Genit Tract Dis, 2019, 23(1): 65-70. DOI: 10.1097/LGT.0000000000000440.
[1] 袁芃. 2023年HER-2阳性乳腺癌治疗进展[J]. 中华乳腺病杂志(电子版), 2024, 18(02): 66-70.
[2] 唐蜜, 蔡江晖, 罗尔丹, 郭文玫, 熊丽玲, 林永红, 邢莎莎, 杨霄. 多肽疫苗治疗乳腺癌的临床研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(05): 309-313.
[3] 王圣睿, 曹国瑞, 谭红略. 防治关节置换术后恶心呕吐的研究进展[J]. 中华关节外科杂志(电子版), 2024, 18(01): 131-136.
[4] 王丽, 王月莺, 周芬, 郭宇堃, 魏丽娜. 促性腺激素释放激素拮抗剂对子宫内膜容受性影响的研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(06): 629-635.
[5] 武渊, 朱必清, 何丹, 王海蓉, 李倩. 采取调强放疗联合后装治疗宫颈癌患者的预后模型及危险分层系统构建[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(06): 734-744.
[6] 马敏榕, 李聪, 周勤. 宫颈癌治疗研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 497-504.
[7] 林昌盛, 战军, 肖雪. 上皮性卵巢癌患者诊疗中基因检测及分子靶向药物治疗[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 505-510.
[8] 顾娟, 孙擎擎, 胡方方, 曹义娟, 祁玉娟. 子宫内膜容受性检测改善胚胎反复种植失败患者妊娠结局的临床应用[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 582-587.
[9] 周东杰, 蒋敏, 范海瑞, 高玲玲, 孔祥, 卢丹, 王丽萍. 非编码RNA在卵泡发育成熟中作用及其机制的研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 387-393.
[10] 陈荟竹, 郭应坤, 汪昕蓉, 宁刚, 陈锡建. 上皮性卵巢癌"二元论模型"的分子生物学研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 394-402.
[11] 韩春颖, 王婷婷, 李艳艳, 朴金霞. 子宫内膜癌患者淋巴管间隙浸润预测因素研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 403-409.
[12] 陈向军, 于丽, 王星, 梁俊青, 吴迪, 李志军. 采用不同方法联合放射治疗修复薄型瘢痕疙瘩的临床疗效分析[J]. 中华损伤与修复杂志(电子版), 2024, 19(03): 215-222.
[13] 叶长缨, 谢静, 丁桂聪. 乳牙龋病的过渡性治疗研究进展[J]. 中华口腔医学研究杂志(电子版), 2023, 17(05): 365-370.
[14] 张成仁, 杨熊飞, 杜斌斌, 柳利利, 李晶晶, 朱成章, 吴德望, 吕耀春. 转移灶不可切除的无症状结直肠癌是否行原发灶肿瘤切除术的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(03): 305-310.
[15] 邱凯锋, 王则远, 何志超, 付凯利, 梅童霖, 关英杰, 高飞, 伍俊妍. 人工智能技术在超说明书用药循证中的应用研究[J]. 中华临床医师杂志(电子版), 2023, 17(12): 1212-1218.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号